The global Non-small Cell Lung Cancer Drugs Market size was valued at US$ 22.450 billion in 2024 and is projected to reach US$ 35.625 billion by 2030, at a CAGR of 8.0% during the forecast period 2024-2030.
The United States Non-small Cell Lung Cancer Drugs Market size was valued at US$ 8.92 billion in 2024 and is projected to US$ 13.45 billion by 2030, at a CAGR of 7.1% during the forecast period 2024-2030.
Pharmaceuticals specifically targeting non-small cell lung cancer.
Patient treatments reached 2.8 million in 2023. Immunotherapies grow at 9.2% annually. Market saw 52% increase in precision medicine. Approvals received in 58 countries. Future projects worth US$ 8.45 billion by 2026. North America leads with 45% market share.
Report Overview
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.
This report provides a deep insight into the global Non-small Cell Lung Cancer Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Non-small Cell Lung Cancer Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Non-small Cell Lung Cancer Drugs market in any manner.
Global Non-small Cell Lung Cancer Drugs Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- AstraZeneca
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Merck & Co., Inc.
- Including or Excluding key companies relevant to your analysis.
Market Segmentation (by Type)
- Biologics
- Small Molecule Targeted Therapy
- Chemotherapy
- Other
Market Segmentation (by Application)
- Lung Adenocarcinoma
- Squamous Cell Lung Carcinoma
- Large-cell Lung Carcinoma
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Non-small Cell Lung Cancer Drugs Market
- Overview of the regional outlook of the Non-small Cell Lung Cancer Drugs Market:
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Non-small Cell Lung Cancer Drugs
1.2 Key Market Segments
1.2.1 Non-small Cell Lung Cancer Drugs Segment by Type
1.2.2 Non-small Cell Lung Cancer Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Non-small Cell Lung Cancer Drugs Market Overview
2.1 Global Market Overview
2.1.1 Global Non-small Cell Lung Cancer Drugs Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Non-small Cell Lung Cancer Drugs Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Non-small Cell Lung Cancer Drugs Market Competitive Landscape
3.1 Global Non-small Cell Lung Cancer Drugs Sales by Manufacturers (2019-2024)
3.2 Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Manufacturers (2019-2024)
3.3 Non-small Cell Lung Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Non-small Cell Lung Cancer Drugs Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Non-small Cell Lung Cancer Drugs Sales Sites, Area Served, Product Type
3.6 Non-small Cell Lung Cancer Drugs Market Competitive Situation and Trends
3.6.1 Non-small Cell Lung Cancer Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Non-small Cell Lung Cancer Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Non-small Cell Lung Cancer Drugs Industry Chain Analysis
4.1 Non-small Cell Lung Cancer Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Non-small Cell Lung Cancer Drugs Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Non-small Cell Lung Cancer Drugs Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Non-small Cell Lung Cancer Drugs Sales Market Share by Type (2019-2024)
6.3 Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Type (2019-2024)
6.4 Global Non-small Cell Lung Cancer Drugs Price by Type (2019-2024)
7 Non-small Cell Lung Cancer Drugs Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Non-small Cell Lung Cancer Drugs Market Sales by Application (2019-2024)
7.3 Global Non-small Cell Lung Cancer Drugs Market Size (M USD) by Application (2019-2024)
7.4 Global Non-small Cell Lung Cancer Drugs Sales Growth Rate by Application (2019-2024)
8 Non-small Cell Lung Cancer Drugs Market Segmentation by Region
8.1 Global Non-small Cell Lung Cancer Drugs Sales by Region
8.1.1 Global Non-small Cell Lung Cancer Drugs Sales by Region
8.1.2 Global Non-small Cell Lung Cancer Drugs Sales Market Share by Region
8.2 North America
8.2.1 North America Non-small Cell Lung Cancer Drugs Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Non-small Cell Lung Cancer Drugs Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Non-small Cell Lung Cancer Drugs Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Non-small Cell Lung Cancer Drugs Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Non-small Cell Lung Cancer Drugs Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 AstraZeneca
9.1.1 AstraZeneca Non-small Cell Lung Cancer Drugs Basic Information
9.1.2 AstraZeneca Non-small Cell Lung Cancer Drugs Product Overview
9.1.3 AstraZeneca Non-small Cell Lung Cancer Drugs Product Market Performance
9.1.4 AstraZeneca Business Overview
9.1.5 AstraZeneca Non-small Cell Lung Cancer Drugs SWOT Analysis
9.1.6 AstraZeneca Recent Developments
9.2 Bristol-Myers Squibb Company
9.2.1 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Basic Information
9.2.2 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Product Overview
9.2.3 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Product Market Performance
9.2.4 Bristol-Myers Squibb Company Business Overview
9.2.5 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs SWOT Analysis
9.2.6 Bristol-Myers Squibb Company Recent Developments
9.3 Eli Lilly and Company
9.3.1 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Basic Information
9.3.2 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Product Overview
9.3.3 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Product Market Performance
9.3.4 Eli Lilly and Company Non-small Cell Lung Cancer Drugs SWOT Analysis
9.3.5 Eli Lilly and Company Business Overview
9.3.6 Eli Lilly and Company Recent Developments
9.4 F. Hoffmann-La Roche Ltd
9.4.1 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Basic Information
9.4.2 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Product Overview
9.4.3 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Product Market Performance
9.4.4 F. Hoffmann-La Roche Ltd Business Overview
9.4.5 F. Hoffmann-La Roche Ltd Recent Developments
9.5 Merck and Co., Inc.
9.5.1 Merck and Co., Inc. Non-small Cell Lung Cancer Drugs Basic Information
9.5.2 Merck and Co., Inc. Non-small Cell Lung Cancer Drugs Product Overview
9.5.3 Merck and Co., Inc. Non-small Cell Lung Cancer Drugs Product Market Performance
9.5.4 Merck and Co., Inc. Business Overview
9.5.5 Merck and Co., Inc. Recent Developments
10 Non-small Cell Lung Cancer Drugs Market Forecast by Region
10.1 Global Non-small Cell Lung Cancer Drugs Market Size Forecast
10.2 Global Non-small Cell Lung Cancer Drugs Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Non-small Cell Lung Cancer Drugs Market Size Forecast by Country
10.2.3 Asia Pacific Non-small Cell Lung Cancer Drugs Market Size Forecast by Region
10.2.4 South America Non-small Cell Lung Cancer Drugs Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Non-small Cell Lung Cancer Drugs by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Non-small Cell Lung Cancer Drugs Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Non-small Cell Lung Cancer Drugs by Type (2025-2030)
11.1.2 Global Non-small Cell Lung Cancer Drugs Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Non-small Cell Lung Cancer Drugs by Type (2025-2030)
11.2 Global Non-small Cell Lung Cancer Drugs Market Forecast by Application (2025-2030)
11.2.1 Global Non-small Cell Lung Cancer Drugs Sales (Kilotons) Forecast by Application
11.2.2 Global Non-small Cell Lung Cancer Drugs Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Non-small Cell Lung Cancer Drugs Market Size Comparison by Region (M USD)
Table 5. Global Non-small Cell Lung Cancer Drugs Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Non-small Cell Lung Cancer Drugs Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Non-small Cell Lung Cancer Drugs Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Non-small Cell Lung Cancer Drugs Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-small Cell Lung Cancer Drugs as of 2022)
Table 10. Global Market Non-small Cell Lung Cancer Drugs Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Non-small Cell Lung Cancer Drugs Sales Sites and Area Served
Table 12. Manufacturers Non-small Cell Lung Cancer Drugs Product Type
Table 13. Global Non-small Cell Lung Cancer Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Non-small Cell Lung Cancer Drugs
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Non-small Cell Lung Cancer Drugs Market Challenges
Table 22. Global Non-small Cell Lung Cancer Drugs Sales by Type (Kilotons)
Table 23. Global Non-small Cell Lung Cancer Drugs Market Size by Type (M USD)
Table 24. Global Non-small Cell Lung Cancer Drugs Sales (Kilotons) by Type (2019-2024)
Table 25. Global Non-small Cell Lung Cancer Drugs Sales Market Share by Type (2019-2024)
Table 26. Global Non-small Cell Lung Cancer Drugs Market Size (M USD) by Type (2019-2024)
Table 27. Global Non-small Cell Lung Cancer Drugs Market Size Share by Type (2019-2024)
Table 28. Global Non-small Cell Lung Cancer Drugs Price (USD/Ton) by Type (2019-2024)
Table 29. Global Non-small Cell Lung Cancer Drugs Sales (Kilotons) by Application
Table 30. Global Non-small Cell Lung Cancer Drugs Market Size by Application
Table 31. Global Non-small Cell Lung Cancer Drugs Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Non-small Cell Lung Cancer Drugs Sales Market Share by Application (2019-2024)
Table 33. Global Non-small Cell Lung Cancer Drugs Sales by Application (2019-2024) & (M USD)
Table 34. Global Non-small Cell Lung Cancer Drugs Market Share by Application (2019-2024)
Table 35. Global Non-small Cell Lung Cancer Drugs Sales Growth Rate by Application (2019-2024)
Table 36. Global Non-small Cell Lung Cancer Drugs Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Non-small Cell Lung Cancer Drugs Sales Market Share by Region (2019-2024)
Table 38. North America Non-small Cell Lung Cancer Drugs Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Non-small Cell Lung Cancer Drugs Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Non-small Cell Lung Cancer Drugs Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Non-small Cell Lung Cancer Drugs Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Non-small Cell Lung Cancer Drugs Sales by Region (2019-2024) & (Kilotons)
Table 43. AstraZeneca Non-small Cell Lung Cancer Drugs Basic Information
Table 44. AstraZeneca Non-small Cell Lung Cancer Drugs Product Overview
Table 45. AstraZeneca Non-small Cell Lung Cancer Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. AstraZeneca Business Overview
Table 47. AstraZeneca Non-small Cell Lung Cancer Drugs SWOT Analysis
Table 48. AstraZeneca Recent Developments
Table 49. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Basic Information
Table 50. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Product Overview
Table 51. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Bristol-Myers Squibb Company Business Overview
Table 53. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs SWOT Analysis
Table 54. Bristol-Myers Squibb Company Recent Developments
Table 55. Eli Lilly and Company Non-small Cell Lung Cancer Drugs Basic Information
Table 56. Eli Lilly and Company Non-small Cell Lung Cancer Drugs Product Overview
Table 57. Eli Lilly and Company Non-small Cell Lung Cancer Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Eli Lilly and Company Non-small Cell Lung Cancer Drugs SWOT Analysis
Table 59. Eli Lilly and Company Business Overview
Table 60. Eli Lilly and Company Recent Developments
Table 61. F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Basic Information
Table 62. F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Product Overview
Table 63. F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. F. Hoffmann-La Roche Ltd Business Overview
Table 65. F. Hoffmann-La Roche Ltd Recent Developments
Table 66. Merck and Co., Inc. Non-small Cell Lung Cancer Drugs Basic Information
Table 67. Merck and Co., Inc. Non-small Cell Lung Cancer Drugs Product Overview
Table 68. Merck and Co., Inc. Non-small Cell Lung Cancer Drugs Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Merck and Co., Inc. Business Overview
Table 70. Merck and Co., Inc. Recent Developments
Table 71. Global Non-small Cell Lung Cancer Drugs Sales Forecast by Region (2025-2030) & (Kilotons)
Table 72. Global Non-small Cell Lung Cancer Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 73. North America Non-small Cell Lung Cancer Drugs Sales Forecast by Country (2025-2030) & (Kilotons)
Table 74. North America Non-small Cell Lung Cancer Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 75. Europe Non-small Cell Lung Cancer Drugs Sales Forecast by Country (2025-2030) & (Kilotons)
Table 76. Europe Non-small Cell Lung Cancer Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 77. Asia Pacific Non-small Cell Lung Cancer Drugs Sales Forecast by Region (2025-2030) & (Kilotons)
Table 78. Asia Pacific Non-small Cell Lung Cancer Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 79. South America Non-small Cell Lung Cancer Drugs Sales Forecast by Country (2025-2030) & (Kilotons)
Table 80. South America Non-small Cell Lung Cancer Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 81. Middle East and Africa Non-small Cell Lung Cancer Drugs Consumption Forecast by Country (2025-2030) & (Units)
Table 82. Middle East and Africa Non-small Cell Lung Cancer Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 83. Global Non-small Cell Lung Cancer Drugs Sales Forecast by Type (2025-2030) & (Kilotons)
Table 84. Global Non-small Cell Lung Cancer Drugs Market Size Forecast by Type (2025-2030) & (M USD)
Table 85. Global Non-small Cell Lung Cancer Drugs Price Forecast by Type (2025-2030) & (USD/Ton)
Table 86. Global Non-small Cell Lung Cancer Drugs Sales (Kilotons) Forecast by Application (2025-2030)
Table 87. Global Non-small Cell Lung Cancer Drugs Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of Non-small Cell Lung Cancer Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Non-small Cell Lung Cancer Drugs Market Size (M USD), 2019-2030
Figure 5. Global Non-small Cell Lung Cancer Drugs Market Size (M USD) (2019-2030)
Figure 6. Global Non-small Cell Lung Cancer Drugs Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Non-small Cell Lung Cancer Drugs Market Size by Country (M USD)
Figure 11. Non-small Cell Lung Cancer Drugs Sales Share by Manufacturers in 2023
Figure 12. Global Non-small Cell Lung Cancer Drugs Revenue Share by Manufacturers in 2023
Figure 13. Non-small Cell Lung Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Non-small Cell Lung Cancer Drugs Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Non-small Cell Lung Cancer Drugs Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Non-small Cell Lung Cancer Drugs Market Share by Type
Figure 18. Sales Market Share of Non-small Cell Lung Cancer Drugs by Type (2019-2024)
Figure 19. Sales Market Share of Non-small Cell Lung Cancer Drugs by Type in 2023
Figure 20. Market Size Share of Non-small Cell Lung Cancer Drugs by Type (2019-2024)
Figure 21. Market Size Market Share of Non-small Cell Lung Cancer Drugs by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Non-small Cell Lung Cancer Drugs Market Share by Application
Figure 24. Global Non-small Cell Lung Cancer Drugs Sales Market Share by Application (2019-2024)
Figure 25. Global Non-small Cell Lung Cancer Drugs Sales Market Share by Application in 2023
Figure 26. Global Non-small Cell Lung Cancer Drugs Market Share by Application (2019-2024)
Figure 27. Global Non-small Cell Lung Cancer Drugs Market Share by Application in 2023
Figure 28. Global Non-small Cell Lung Cancer Drugs Sales Growth Rate by Application (2019-2024)
Figure 29. Global Non-small Cell Lung Cancer Drugs Sales Market Share by Region (2019-2024)
Figure 30. North America Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Non-small Cell Lung Cancer Drugs Sales Market Share by Country in 2023
Figure 32. U.S. Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Non-small Cell Lung Cancer Drugs Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Non-small Cell Lung Cancer Drugs Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Non-small Cell Lung Cancer Drugs Sales Market Share by Country in 2023
Figure 37. Germany Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Non-small Cell Lung Cancer Drugs Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Non-small Cell Lung Cancer Drugs Sales Market Share by Region in 2023
Figure 44. China Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Non-small Cell Lung Cancer Drugs Sales and Growth Rate (Kilotons)
Figure 50. South America Non-small Cell Lung Cancer Drugs Sales Market Share by Country in 2023
Figure 51. Brazil Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Non-small Cell Lung Cancer Drugs Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Non-small Cell Lung Cancer Drugs Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Non-small Cell Lung Cancer Drugs Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Non-small Cell Lung Cancer Drugs Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Non-small Cell Lung Cancer Drugs Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Non-small Cell Lung Cancer Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Non-small Cell Lung Cancer Drugs Market Share Forecast by Type (2025-2030)
Figure 65. Global Non-small Cell Lung Cancer Drugs Sales Forecast by Application (2025-2030)
Figure 66. Global Non-small Cell Lung Cancer Drugs Market Share Forecast by Application (2025-2030)
